Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H25NO3 |
Molecular Weight | 339.4281 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6
InChI
InChIKey=WJBLNOPPDWQMCH-MBPVOVBZSA-N
InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
Molecular Formula | C21H25NO3 |
Molecular Weight | 339.4281 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Nalmefene is the first medication approved for alcoholism
with the primary goal of reducing alcohol intake in an as
needed approach. Nalmefene
received a marketing authorization valid throughout the
European Union on February 25, 2013 and is under development
in Asia. Nalmefene is an opioid system modulator with a
distinct μ, δ, and κ receptor profile. In vitro studies have demonstrated
that Nalmefene is a selective opioid receptor ligand
with antagonist activity at the μ and δ receptors and partial
agonist activity at the κ receptor. In vivo studies have demonstrated
that nalmefene reduces alcohol consumption, possibly
by modulating cortico-mesolimbic functions. In the US, immediate-release injectable nalmefene was approved in 1995 as an antidote for opioid overdose. It was sold under the trade name Revex. The product was discontinued by its manufacturer around 2008. Currently Nalmefene is sold under the trade name Selincro. Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level, without physical withdrawal symptoms and who do not require immediate detoxification.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.44 nM [Ki] | |||
9.3 nM [Ki] | |||
0.12 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Selincro Approved UseSelincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level, without physical withdrawal symptoms and who do not require immediate detoxification. Launch Date2013 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
57.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
155 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
177 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
274 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1320 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1876 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
314 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
109 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
6 mg single, intravenous dose: 6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
191 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
12 mg single, intravenous dose: 12 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
385 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
24 mg single, intravenous dose: 24 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/ |
1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
29.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/ |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3680580/ |
20 mg 2 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
6 mg single, intravenous dose: 6 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
12 mg single, intravenous dose: 12 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3943269/ |
24 mg single, intravenous dose: 24 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/ |
1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8877019/ |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NALMEFENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
18 mg 1 times / day steady, oral Recommended Dose: 18 mg, 1 times / day Route: oral Route: steady Dose: 18 mg, 1 times / day Sources: |
unhealthy, 39 years |
Disc. AE: Psychiatric decompensation... AEs leading to discontinuation/dose reduction: Psychiatric decompensation (1 patient) Sources: |
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
healthy, adult |
|
300 mg single, oral Highest studied dose |
healthy, adult |
|
0.75 ug/kg single, intravenous Highest studied dose Dose: 0.75 ug/kg Route: intravenous Route: single Dose: 0.75 ug/kg Sources: |
unhealthy, adult |
DLT: Anesthesia reversal... Dose limiting toxicities: Anesthesia reversal (2 patients) Sources: |
0.5 ug/kg single, intravenous MTD Dose: 0.5 ug/kg Route: intravenous Route: single Dose: 0.5 ug/kg Sources: |
unhealthy, adult |
DLT: Anesthesia reversal... Dose limiting toxicities: Anesthesia reversal (3 patients) Sources: |
20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: |
unhealthy, adult |
Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness (1 patient) Sources: |
5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: |
unhealthy, adult |
Disc. AE: Dizziness, Rash... AEs leading to discontinuation/dose reduction: Dizziness (1 patient) Sources: Rash (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Psychiatric decompensation | 1 patient Disc. AE |
18 mg 1 times / day steady, oral Recommended Dose: 18 mg, 1 times / day Route: oral Route: steady Dose: 18 mg, 1 times / day Sources: |
unhealthy, 39 years |
Anesthesia reversal | 2 patients DLT |
0.75 ug/kg single, intravenous Highest studied dose Dose: 0.75 ug/kg Route: intravenous Route: single Dose: 0.75 ug/kg Sources: |
unhealthy, adult |
Anesthesia reversal | 3 patients DLT |
0.5 ug/kg single, intravenous MTD Dose: 0.5 ug/kg Route: intravenous Route: single Dose: 0.5 ug/kg Sources: |
unhealthy, adult |
Dizziness | 1 patient Disc. AE |
20 mg 2 times / day steady, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: |
unhealthy, adult |
Dizziness | 1 patient Disc. AE |
5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: |
unhealthy, adult |
Rash | 1 patient Disc. AE |
5 mg 2 times / day steady, oral Studied dose Dose: 5 mg, 2 times / day Route: oral Route: steady Dose: 5 mg, 2 times / day Sources: |
unhealthy, adult |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Nalmefene: intravenous safety and kinetics of a new opioid antagonist. | 1986 Jan |
|
A panic attack precipitated by opiate blockade--a case study. | 1987 Oct |
|
Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys. | 2002 Oct |
|
Characterization of scratching responses in rats following centrally administered morphine or bombesin. | 2003 Nov |
|
Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats. | 2004 Feb |
|
Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. | 2004 Jul 8 |
|
Phobic memory and somatic vulnerabilities in anorexia nervosa: a necessary unity? | 2005 Sep 6 |
|
Epidemiologic and clinical updates on impulse control disorders: a critical review. | 2006 Dec |
|
Pathological gambling: focusing on the addiction, not the activity. | 2006 Feb |
|
Pharmacologic treatments for opioid dependence: detoxification and maintenance options. | 2007 |
|
Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy. | 2007 Mar-Apr |
|
Emerging pharmacologic options for treating postoperative ileus. | 2007 Oct 15 |
|
Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. | 2007 Sep 24 |
|
Imaging of opioid receptors in the central nervous system. | 2008 May |
|
The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. | 2009 Mar 31 |
|
Primary biliary cirrhosis. | 2009 Sep |
|
The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. | 2010 |
|
Pathological gambling and compulsive buying: do they fall within an obsessive-compulsive spectrum? | 2010 |
|
Opioid antagonists for alcohol dependence. | 2010 Dec 8 |
|
Nalmefene for treatment of alcohol dependence. | 2010 Nov |
Patents
Sample Use Guides
How much to take
- The recommended dose is one tablet on days when you think there is a risk you will drink alcohol
- The maximum dose is one tablet per day.
How and when to take
- You should take the tablet 1-2 hours before you start drinking alcohol.
- Swallow the tablet whole, do not crush or divide the tablet.
- You can take Selincro (Nalmefene) with or without food.
Each film-coated tablet contains 18.06 mg nalmefene (as hydrochloride dihydrate).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2991678
Nalmefene antagonized the bindings of [3H]-dihydromorphine, [3H]-ethylketocyclazocine and [3H]-D-ala-D-leu enkephalin with IC50's in the low nanomolar range in rat brain membranes.. At the central mu receptor, nalmefene bound with an IC50 of 1.0 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:29:34 GMT 2025
by
admin
on
Wed Apr 02 09:29:34 GMT 2025
|
Record UNII |
TOV02TDP9I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
||
|
NDF-RT |
N0000000154
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
||
|
WHO-VATC |
QN07BB05
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
||
|
WHO-ATC |
N07BB05
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
||
|
NDF-RT |
N0000175691
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
||
|
LIVERTOX |
NBK548295
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C038981
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
5189
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
SUB09139MIG
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
NALMEFENE
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
C61855
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
T-2
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
1628
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
TOV02TDP9I
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL982
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
TOV02TDP9I
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
1876
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
55096-26-9
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
DB06230
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
DTXSID8023347
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
5284594
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
6761
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
100000084441
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | |||
|
31479
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
m7715
Created by
admin on Wed Apr 02 09:29:34 GMT 2025 , Edited by admin on Wed Apr 02 09:29:34 GMT 2025
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||